NL-OMON37414撤回不适用
GHB neurotoxicity, brain damage due to GHB-induced coma in recreational GHB users - GHB neurotox
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Age 18-40 years.
- •Participants in groups 1-3 have a life time prevalence of GHB use of 25 times or more.
- •Expressed willingness to participate to experimental part in AMC.
排除标准
- •Subjects/patients with epilepsy.
- •Heavy alcohol use (> 20 drinks) on at least one occasion in the last year.
- •General anaesthesia in the last year.
- •With respect to MRI imaging: claustrophobia; presence of non-removable metal objects, use of psychotropic
- •medication.
- •. Pregnant or breast-feeding mothers
- •Use of ketamine or speed is no exclusion criterion, but will be registered
研究者
相似试验
已完成
不适用
Brain damage due to GHB-induced coma in GHB users.cognitive and memory damage10042258NL-OMON40636Academisch Medisch Centrum81
已完成
不适用
Clinicopathological study of neuro-glial damage biomarkers in central nervous system diseasesMultiple Sclerosis and allied disordersJPRN-UMIN000006221Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine150
已完成
1 期
Higher brain dysfunction after traumatic brain injury: association with serotonin transporter deficiency.JPRN-UMIN000015456Hokkaido University20
撤回
1 期
GHB Withdrawal Symptoms and Effectiveness of Treatment With Lorazepam Versus Pentobarbital - 1Substance-Related DisordersNCT00123578University of California, Los Angeles
已完成
不适用
The effects of galantamine administration on brain network topology in patients with Alzheimer's disease (AD): A possible new biomarker for pharmacotherapy of ADmild to moderate Alzhiemer's diseaseJPRN-UMIN000018749atinal Center of Neurology and Psychiatry9